Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Xenon (XENE) and Arcus Biosciences (RCUS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biomea Fusion (BMEA – Research Report), Xenon (XENE – Research Report) and Arcus Biosciences (RCUS – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Biomea Fusion (BMEA)

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Biomea Fusion today and set a price target of $9.00. The company’s shares closed last Monday at $2.67, close to its 52-week low of $2.27.

According to TipRanks.com, Biegler ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.8% and a 38.2% success rate. Biegler covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Day One Biopharmaceuticals, and Acrivon Therapeutics, Inc. ;'>

Currently, the analyst consensus on Biomea Fusion is a Strong Buy with an average price target of $7.00, a 222.6% upside from current levels. In a report issued on September 23, Piper Sandler also reiterated a Buy rating on the stock with a $7.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Xenon (XENE)

Chardan Capital analyst Rudy Li reiterated a Buy rating on Xenon today and set a price target of $55.00. The company’s shares closed last Monday at $39.55.

According to TipRanks.com, Li is a 4-star analyst with an average return of 23.6% and a 56.5% success rate. Li covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Praxis Precision Medicines, and Centessa Pharmaceuticals. ;'>

Currently, the analyst consensus on Xenon is a Strong Buy with an average price target of $55.00, which is a 38.8% upside from current levels. In a report released today, William Blair also reiterated a Buy rating on the stock.

Arcus Biosciences (RCUS)

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Arcus Biosciences, with a price target of $23.00. The company’s shares closed last Monday at $14.48.

According to TipRanks.com, Flynn is a 4-star analyst with an average return of 4.5% and a 56.5% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Vertex Pharmaceuticals, and Bristol-Myers Squibb. ;'>

Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $31.10, a 125.4% upside from current levels. In a report issued on September 30, Barclays also maintained a Buy rating on the stock with a $14.00 price target.

Read More on BMEA:

Disclaimer & DisclosureReport an Issue

• Closing Bell Movers: Constellation Brands up 3% on earnings beat
• Biomea Fusion Announces Positive Phase II Study Results
• Biomea Fusion announces 52-week results from COVALENT-111 study
• Biomea Fusion announces offering of common stock and warrants, no amount given
• Biomea Fusion reports inducment grants under Nasdaq listing rule